Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trialJavier Cortés, Gallardo Carlos, Hiroji Iwata et al.|The Lancet|2020Cited by 1.8k
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 studyErica L. Mayer, Michael Gnant, Amylou C. Dueck et al.|The Lancet Oncology|2021Cited by 255
Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Seock‐Ah Im et al.|New England Journal of Medicine|2024Cited by 235
Diagnostic yield and safety of endoscopic-ultrasound guided trucut biopsy in patients with gastric submucosal tumors: a prospective studyMarcin Polkowski, E Butruk, W Gerke et al.|Endoscopy|2009Cited by 128
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, Erica L. Mayer et al.|New England Journal of Medicine|2025Cited by 106